In a patient with a history of spondylolisthesis who now has an irresistible urge to move her legs while sitting or lying down, what is the most likely diagnosis and what evaluation and treatment steps are recommended?

Diagnosis: Restless Legs Syndrome (RLS)

This patient has Restless Legs Syndrome (RLS), characterized by the irresistible urge to move her legs when sitting or lying down 1, 2. The spondylolisthesis is likely coincidental and not the primary cause of these specific symptoms.

Diagnostic Confirmation

RLS is diagnosed clinically when all four essential criteria are met 1, 2:

• Urge to move the legs (often with uncomfortable sensations)
• Symptoms worsen with rest/inactivity (sitting or lying down)
• Relief with movement (walking, stretching)
• Symptoms worse in evening/night

Your patient clearly meets these criteria. No polysomnography is needed for diagnosis 2.

Immediate Evaluation Steps

Check iron studies immediately 1, 2:

• Serum ferritin
• Transferrin saturation

These are the only essential laboratory tests. Iron deficiency is a treatable cause even with "normal" levels.

Treatment Algorithm

Step 1: Iron Supplementation (First-Line for Low Iron)

If ferritin ≤100 ng/mL OR transferrin saturation <20%:

• Start ferrous sulfate 325-650 mg daily or every other day 1, 2
• This is first-line therapy before any other medication
• Continue for 3 months, then recheck levels

Step 2: Pharmacologic Treatment (If Iron Insufficient or Symptoms Severe)

First-line medication: Gabapentinoids 1, 2

• Gabapentin or pregabalin are preferred initial pharmacologic options
• Approximately 70% of patients improve significantly versus 40% with placebo 2
• These avoid the augmentation risk associated with dopamine agonists

Avoid dopamine agonists as standard first-line therapy 1:

• The 2025 AASM guidelines suggest against standard use of pramipexole, ropinirole, and rotigotine 1
• These carry 7-10% annual risk of augmentation (iatrogenic worsening of RLS) 2
• May be considered only for short-term use in patients who prioritize immediate symptom relief over long-term adverse effects 1

Step 3: Alternative Options

If gabapentinoids fail or are not tolerated:

• Opioids (extended-release oxycodone, methadone 5-10 mg daily) are suggested as second-line 1, 2
• Dipyridamole is an option with lower certainty evidence 1

Step 4: Intravenous Iron

For refractory cases or intolerance to oral iron:

• IV ferumoxytol 1000 mg can be used even with ferritin ≤100 ng/mL 1, 2
• Particularly useful if augmentation develops with dopamine agonists 3

Critical Pitfalls to Avoid

Do NOT use these medications 1:

• Cabergoline (strong recommendation against) 1
• Bupropion, carbamazepine, clonazepam, valproic acid (all suggested against) 1
• Avoid dopamine antagonists and centrally acting H1 antihistamines (diphenhydramine) as they worsen RLS 2

Watch for augmentation if dopamine agonists are used 3, 2:

• Earlier symptom onset during the day
• Increased symptom intensity
• Spread to arms or other body regions
• Requires switching to alternative therapy

Practical Management Approach

Start with this sequence:

1. Check ferritin and transferrin saturation today
2. If ferritin ≤100 ng/mL or transferrin saturation <20%: start ferrous sulfate 325 mg daily or every other day
3. If symptoms require immediate pharmacologic relief or iron is adequate: start gabapentin (typical dose 300-1200 mg at bedtime) or pregabalin
4. Discontinue any exacerbating medications (antidepressants, antihistamines, dopamine blockers) if possible 2
5. Reserve dopamine agonists only for patients who fail gabapentinoids and understand augmentation risk

The 2025 AASM guidelines represent a major shift away from dopamine agonists toward gabapentinoids and iron supplementation as preferred first-line approaches 1, 2.